# SAMSARA BIOCAPITAL, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1744967. Source: https://holderbook.com/funds/1744967-samsara-biocapital-llc/

- Reported value: $1.2B
- Positions: 24
- Weight of the ten largest: 90.5%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| SCHOLAR ROCK HLDG CORP | [SRRK](https://holderbook.com/stocks/SRRK/) | $379.4M | 6,897,652 | 31.2% | 18 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $178.6M | 6,345,219 | 14.7% | 8 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $158.4M | 5,871,018 | 13.0% | 14 |
| SEPTERNA INC | [SEPN](https://holderbook.com/stocks/SEPN/) | $105.5M | 3,149,128 | 8.7% | 7 |
| ALAMAR BIOSCIENCES INC | [ALMR](https://holderbook.com/stocks/ALMR/) | $67.2M | 2,480,310 | 5.5% | 1 |
| NEUROGENE INC | [NGNE](https://holderbook.com/stocks/NGNE/) | $54.0M | 1,717,127 | 4.4% | 11 |
| KALARIS THERAPEUTICS INC | [KLRS](https://holderbook.com/stocks/KLRS/) | $52.4M | 12,881,175 | 4.3% | 6 |
| SPYGLASS PHARMA INC | [SGP](https://holderbook.com/stocks/SGP/) | $47.0M | 2,109,953 | 3.9% | 2 |
| SUTRO BIOPHARMA INC | [STRO](https://holderbook.com/stocks/STRO/) | $35.3M | 1,062,872 | 2.9% | 3 |
| INVENTIVA SA | [IVA](https://holderbook.com/stocks/IVA/) | $23.9M | 6,314,805 | 2.0% | 3 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $16.4M | 736,237 | 1.3% | 5 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $15.2M | 556,044 | 1.3% | 1 |
| VTV THERAPEUTICS INC | [VTVT](https://holderbook.com/stocks/VTVT/) | $11.2M | 298,496 | 0.9% | 11 |
| AQUESTIVE THERAPEUTICS INC | [AQST](https://holderbook.com/stocks/AQST/) | $10.4M | 2,500,000 | 0.9% | 4 |
| NKARTA INC | [NKTX](https://holderbook.com/stocks/NKTX/) | $9.9M | 3,507,666 | 0.8% | 24 |
| ARTIVA BIOTHERAPEUTICS INC | [ARTV](https://holderbook.com/stocks/ARTV/) | $9.3M | 954,861 | 0.8% | 1 |
| RANI THERAPEUTICS HLDGS INC | [RANI](https://holderbook.com/stocks/RANI/) | $7.9M | 10,369,159 | 0.6% | 3 |
| AGOMAB THERAPEUTICS NV | [AGMB](https://holderbook.com/stocks/AGMB/) | $7.8M | 600,000 | 0.6% | 2 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $7.3M | 55,095 | 0.6% | 4 |
| X4 PHARMACEUTICALS INC | [XFOR](https://holderbook.com/stocks/XFOR/) | $6.5M | 1,395,587 | 0.5% | 3 |
| ELOXX PHARMACEUTICALS INC | - | $5.6M | 400,000 | 0.5% | 1 |
| COHERUS ONCOLOGY INC | [CHRS](https://holderbook.com/stocks/CHRS/) | $4.8M | 3,428,571 | 0.4% | 2 |
| UPSTREAM BIO INC | [UPB](https://holderbook.com/stocks/UPB/) | $2.4M | 353,717 | 0.2% | 7 |
| GOSSAMER BIO INC | [GOSS](https://holderbook.com/stocks/GOSS/) | $1.2M | 7,222,559 | 0.1% | 12 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +10.6% | +14.8% | -4.2% | 99% |
| Q1 2026 | -3.0% | -4.6% | +1.6% | 100% |
| Q4 2025 | +23.4% | +2.4% | +21.0% | 100% |
| Q3 2025 | +59.1% | +7.8% | +51.3% | 96% |
| Q2 2025 | -5.6% | +10.5% | -16.0% | 99% |
| Q1 2025 | -31.2% | -4.6% | -26.6% | 100% |
| Q4 2024 | +29.6% | +2.1% | +27.5% | 100% |
| Q3 2024 | +4.5% | +5.4% | -1.0% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.2B | 24 |
| Q1 2026 | $1.0B | 22 |
| Q4 2025 | $969.3M | 21 |
| Q3 2025 | $765.9M | 27 |
| Q2 2025 | $488.9M | 29 |
| Q1 2025 | $560.8M | 37 |
| Q4 2024 | $728.6M | 43 |
| Q3 2024 | $520.3M | 42 |
| Q2 2024 | $477.8M | 40 |
| Q1 2024 | $646.4M | 39 |
| Q4 2023 | $642.8M | 41 |
| Q3 2023 | $326.7M | 41 |